In this episode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including recent approvals from the House Energy and Commerce Subcommittee on Health and Phase 3 clinical trial results for oral semaglutide to treat obesity.
Podcast Tags: healthcare, healthcare news, health plans, life sciences, health policy, public health, Medicare, drug prices, PBMs, 340B, obesity
Source Links:
- A key House panel approved a slew of health policies. Here's a look at 4 of them
- Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
- Anti-obesity medications are set to skyrocket this year. But how will we afford them?
- What Could New Anti-Obesity Drugs Mean for Medicare?
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Mindy McGrath, Healthcare Industry Advisor and Head of Public Health Sector
Ryan Hummel, Executive and Head of Provider Sector
Jen Burke, Healthcare Industry Strategist
You Might Like
